Cargando…

Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects

Type B adverse drug reactions (ADRs) represent a significant threat as their occurrence arises unpredictable and despite proper application of the drug. The severe immune reaction Abacavir Hypersensitivity Syndrome (AHS) that arises in HIV(+) patients treated with the antiretroviral drug Abacavir (A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gall, Eline, Stieglitz, Florian, Pich, Andreas, Behrens, Georg Martin Norbert, Kuhn, Joachim, Blasczyk, Rainer, Haukamp, Funmilola Josephine, Bade-Döding, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945713/ https://www.ncbi.nlm.nih.gov/pubmed/35327495 http://dx.doi.org/10.3390/biomedicines10030693

Ejemplares similares

Unravelling the Proteomics of HLA-B*57:01(+) Antigen Presenting Cells during Abacavir Medication
por: Haukamp, Funmilola Josephine, et al.
Publicado: (2022)

HLA-B*57:01/Carbamazepine-10,11-Epoxide Association Triggers Upregulation of the NFκB and JAK/STAT Pathways
por: Haukamp, Funmilola Josephine, et al.
Publicado: (2023)

HLA-F Allele-Specific Peptide Restriction Represents an Exceptional Proteomic Footprint
por: Hò, Gia-Gia T., et al.
Publicado: (2019)

HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues
por: Hò, Gia-Gia T., et al.
Publicado: (2019)

The microstructure in the placenta is influenced by the functional diversity of HLA-G allelic variants
por: Stieglitz, F., et al.
Publicado: (2019)

Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02
por: Simper, Gwendolin S., et al.
Publicado: (2018)

The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch
por: Celik, Alexander A., et al.
Publicado: (2015)

HLA-G peptide preferences change in transformed cells: impact on the binding motif
por: Celik, Alexander A., et al.
Publicado: (2018)

The Loss of HLA-F/KIR3DS1 Ligation Is Mediated by Hemoglobin Peptides
por: Hò, Gia-Gia T., et al.
Publicado: (2020)

The polymorphism at residue 156 determines the HLA-B*35 restricted peptide repertoire during HCMV infection
por: Abels, Wiebke C., et al.
Publicado: (2018)

HLA-E: Presentation of a Broader Peptide Repertoire Impacts the Cellular Immune Response—Implications on HSCT Outcome
por: Kraemer, Thomas, et al.
Publicado: (2015)

The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity
por: Simper, Gwendolin S., et al.
Publicado: (2019)

ProTide generated long-acting abacavir nanoformulations
por: Lin, Zhiyi, et al.
Publicado: (2018)

Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration
por: Sabin, Caroline A., et al.
Publicado: (2016)

Abacavir forms novel cross-linking abacavir protein adducts in patients
por: Meng, Xiaoli, et al.
Publicado: (2014)

The Binary Toxin of Clostridioides difficile Alters the Proteome and Phosphoproteome of HEp-2 Cells
por: Stieglitz, Florian, et al.
Publicado: (2021)

HLA-E: A Novel Player for Histocompatibility
por: Kraemer, Thomas, et al.
Publicado: (2014)

Abacavir-induced liver toxicity
por: Pezzani, Maria Diletta, et al.
Publicado: (2016)

Soluble HLA Technology as a Strategy to Evaluate the Impact of HLA Mismatches
por: Kunze-Schumacher, Heike, et al.
Publicado: (2014)

Abacavir methanol 2.5-solvate
por: Pham, Phuong-Truc T.
Publicado: (2009)

Alopecia Areata Associated with Abacavir Therapy
por: Kim, Hee-Sung, et al.
Publicado: (2014)

Regulation of the immune tolerance system determines the susceptibility to HLA-mediated abacavir-induced skin toxicity
por: Susukida, Takeshi, et al.
Publicado: (2021)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
por: M. Llibre, Josep, et al.
Publicado: (2016)

Relaxation Effect of Abacavir on Rat Basilar Arteries
por: Li, Rachel Wai Sum, et al.
Publicado: (2015)

Structural Elements Recognized by Abacavir-Induced T Cells
por: Yerly, Daniel, et al.
Publicado: (2017)

Abacavir use is associated with increased prothrombin conversion
por: Yan, Qiuting, et al.
Publicado: (2023)

AOP-Based Transformation of Abacavir in Different Environments: Evolution Profile of Descyclopropyl-Abacavir and In Silico Toxicity Assessment of the Main Transformation Products
por: Evgenidou, Eleni, et al.
Publicado: (2023)

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
por: Llibre, Josep M., et al.
Publicado: (2016)

A Micropolymorphism Altering the Residue Triad 97/114/156 Determines the Relative Levels of Tapasin Independence and Distinct Peptide Profiles for HLA-A(*)24 Allotypes
por: Badrinath, Soumya, et al.
Publicado: (2014)

Abacavir/lamivudine combination in the treatment of HIV: a review
por: Sivasubramanian, Geetha, et al.
Publicado: (2010)

HLA-B*5701 testing to predict abacavir hypersensitivity
por: Ma, Joseph D., et al.
Publicado: (2010)

The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome
por: Fodor, James, et al.
Publicado: (2019)

Battle between Host Immune Cellular Responses and HCMV Immune Evasion
por: Manandhar, Trishna, et al.
Publicado: (2019)

Stress Degradation Behavior of Abacavir Sulfate and Development of a Suitable Stability-Indicating UHPLC Method for the Determination of Abacavir, its Related Substances, and Degradation Products
por: Vukkum, Pallavi, et al.
Publicado: (2012)

Molecular Recognition of the Antiretroviral Drug Abacavir: Towards the Development of a Novel Carbazole-Based Fluorosensor
por: Idzik, Krzysztof Ryszard, et al.
Publicado: (2011)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
por: Janneh, Omar, et al.
Publicado: (2011)

Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan†
por: Kurita, Tomoko, et al.
Publicado: (2014)

Abacavir-Reactive Memory T Cells Are Present in Drug Naïve Individuals
por: Lucas, Andrew, et al.
Publicado: (2015)

Regional Experience of Abacavir: Valuable but Still has Unanswered Question
por: Bang, Ji Hwan
Publicado: (2017)

Comparison of Chemical and Electrochemical Approaches to Abacavir Oxidative Stability Testing
por: Pražáková, Lucie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bb13niu9n0ogkc2rpvssp8q562